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Introduction {#sec1}
============

The *Drosophila dac* gene is a key member of the retinal determination gene network, which also includes *eyes absent*, *eyeless*, *twin of eyeless*, *teashirt*, and *sine oculis*. Initially cloned as a dominant inhibitor of a hyperactive *egfr* allele in *Drosophila*, *dac* interacts with the epidermal growth factor receptor, decapentaplegic, and Wingless pathways ([@bib11], [@bib12]). *Dac* functions to promote organismal development ([@bib15]), and *Dac* mutant flies have atretic organs ([@bib15]). Reduced DACH1 (the mammalian ortholog of *Dac*) expression has been observed in several malignancies including breast, prostate, lung, and endometrial cancer ([@bib9], [@bib33], [@bib53], [@bib52], [@bib54], [@bib49], [@bib55]) (reviewed in [@bib55]). Clinical studies have demonstrated a correlation between poor prognosis and reduced expression of DACH1 in breast cancer ([@bib53]), and DACH1 re-expression was sufficient to inhibit breast cancer tumor metastasis in mice ([@bib51]). The mammalian DACH1 regulates expression of target genes in part through intrinsic DNA sequence-specific binding to Forkhead binding sites and in part through interacting with DNA-binding transcription factors (c-Jun, SMADs, Six, and ERα) ([@bib39], [@bib53], [@bib52], [@bib57]).

*Dach1* homozygous null mice die at birth, indicating that DACH1 governs essential functions in the organism; however, no morphologic and metabolic alterations have been observed in the analyzed organs ([@bib14]). Given the precedent for *Dac* promoting organismal development, we sought to define the role for DACH1 function in normal development by examining the role of DACH1 in normal post-natal mammary gland development. Given the importance of mammary stem cells in normal mammary gland development ([@bib47]), and the prior studies demonstrating that DACH1 restrains breast cancer stem cell expansion ([@bib50]), we conducted careful analysis of the mammary gland developmental hierarchy through generating temporally regulated *Dach1*^*fl/fl*^ transgenics.

The current studies were conducted to determine the role of DACH1 in normal mammary gland development. These studies revealed an unexpected role for DACH1 to expand the murine mammary gland progenitor cell pool, and to promote ductal formation. We show that endogenous DACH1 restrains transforming growth factor β (TGF-β) signaling in the murine mammary gland and show that Dach1 governs SARA (also known as the zinc finger FYVE domain-containing protein 9 \[ZFYVE9\]) abundance and binding to Smad2/3. Given the importance of TGF-β signaling in development and disease, the finding herein that endogenous DACH1 restrains TGF-β signaling *in vivo* may have broad importance to human disease.

Results {#sec2}
=======

Temporally Regulated Excision of the *Dach1* Gene in the Murine Mammary Gland Reduces Cell Proliferation and Ductal Branching {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------

To examine the physiological role of DACH1 in post-natal mammary gland development, transgenic mice were developed in which *Dach1*^*fl/fl*^ transgenics ([@bib10]) were intercrossed with the *ROSA26*^*CreERT2*^ transgenics. This mouse strain expresses Cre-ERT2 from the ubiquitously expressed *ROSA26* locus. Cre activity utilizes a mutant estrogen hormone-binding domain (ER^T^) to keep Cre inactive unless the non-steroidal estrogen analog 4-hydroxytamoxifen is present. To follow the efficiency of temporal and spatial regulation of Cre recombination *in vivo* and in primary cells derived from these mice, bitransgenic mice were intercrossed with double-fluorescent Cre reporter mice (*ROSA2*6-mTmG^fl/fl^). The *ROSA2*6-mTmG^fl/fl^ transgenics express membrane-targeted tandem dimer Tomato (mT), and after Cre-mediated excision express membrane-targeted GFP (mG) ([@bib32]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Tri-transgenic mice at 6 weeks of age were treated with a pulse of tamoxifen and analyzed after a subsequent 2.5 months ([Figure 1](#fig1){ref-type="fig"}A). Previous studies had shown that this dose of tamoxifen was without effect on mammary repopulating numbers or on pubertal ductal development at this time of analysis ([@bib41]). Furthermore, comparison was made herein between tamoxifen-treated transgenics and tamoxifen-treated control transgenics throughout to avoid any potential independent effect of tamoxifen. Genomic DNA analysis of these mice demonstrated the excision of the first exon of *Dach1* ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Mammary gland fluorescence without tamoxifen was red throughout the mammary gland and epithelial cells ([Figure 1](#fig1){ref-type="fig"}B). *Dach1*^*wt/wt*^-*ROSA26*^*CreERT2*^ mice, which were treated with tamoxifen as a control in the studies, showed efficient excision of the mT transgene and conversion to green fluorescence throughout the mammary gland, without alteration in Dach1 abundance ([Figure 1](#fig1){ref-type="fig"}B). Treatment of *Dach1*^*fl/fl*^*-ROSA26*^*CreERT2*^ mice with tamoxifen resulted in the induction of GFP in the mammary gland ([Figure 1](#fig1){ref-type="fig"}Bf versus Bi Bl) and DACH1 protein, identified by immunohistochemistry as primarily in the basal cells, was abrogated upon tamoxifen treatment ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Inducible *Dach1* Deletion in Mouse Mammary Gland(A) Schematic representation of the tamoxifen treatment schedule for the multigenic *Dach1* transgenics (*Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mT-mGfl*^). (B) Fluorescence microscopy showed the tamoxifen-induced Cre recombinase activity by Tomato-GFP color transformation. (a--c) *Dach1*^*fl/wt*^*ROSA26*^*wt/CreERT2*^ mammary gland without tamoxifen treatment (negative control without Cre reporter and Cre induction) showing GFP (mG) and tomato red fluorescence (mT) are both negative. (b--f) *Dach1*^*fl/wt*^*ROSA26*^*CreERT2/mTmGfl*^ mammary gland without tamoxifen treatment (negative control without Cre induction) showing presence of mT without mG. (g--i) *Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmGfl*^ and (j--l) *Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmGfl*^ mammary gland with tamoxifen treatment used for the *Dach1* deletion mice analysis shows strong mG and weak mT. The combined images showing mT to mG switch in the mammary ducts after tamoxifen treatment. (C) Immunohistochemical staining for DACH1 protein in the mammary gland of the treated mice (*Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmGfl*^ and *Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmGfl*^).

DACH1 Is Expressed in Multipotent Fetal Mammary Stem Cells and in Both the Adult Basal and ERα^+^ Luminal Cells {#sec2.2}
---------------------------------------------------------------------------------------------------------------

In order to examine the expression of *Dach1* by mammary gland cell type, we interrogated two recently published single-cell RNA sequencing (scRNA-seq) studies that had identified mammary gland cellular subtypes ([@bib3], [@bib19]). scRNA-seq transcriptomes annotated by stage of development were generated from Epcam^+^ mammary epithelial cells (MECs), derived from developing (embryonic day 16 \[E16\] and E18), post-natal day (P4) and adult mouse mammary tissues ([@bib19]) ([Figure 2](#fig2){ref-type="fig"}A). The accession number for these data is GEO: [GSE106273](ncbi-geo:GSE106273){#intref0010} and GEO: [GSE111113](ncbi-geo:GSE111113){#intref0015}. Relatedness of individual cell transcriptomes was plotted according to diffusion components (DCs) using the webtool (<http://uofuhealth.utah.edu/huntsman/labs/spike/d3.php>) as previously described ([@bib19]). The diffusion map provides a noise-tolerant, nonlinear dimensionality reduction method, revealing a global topology of the data based on local similarities between individual Epcam^+^ MECs. In this map, DC1 reflects a continuum of relative basal to luminal character. DC2 reflects developmental time from primitive (E16 and E18) at one extreme to P4 to adult mammary cells at the other extreme of the DC2 axis. The abundance of Dach1 transcripts was then assessed in the diffusion map, in order to show the correlation with stage of development and relative abundance in the luminal versus basal subtypes ([Figure 2](#fig2){ref-type="fig"}B). *Dach1* expression was detected in early developmental stages including among multipotent fetal mammary stem cells (fMaSCs) in the embryo and mixed lineage precursors (MMPr) prior to puberty ([Figure 2](#fig2){ref-type="fig"}B). *Dach1* expression was also detected in adult basal cells and ERα^+^ luminal progenitors.Figure 2*Dach1* RNA Transcripts in Mammary Epithelial Cells during Development(A) Diffusion map of single-cell RNA sequencing (scRNA-seq) transcriptomes annotated by stage of development. Epcam^+^ mammary epithelial cells (MECs) were derived from developing (embryonic day 16 \[E16\] and E18), post-natal day (P4) and adult MECs ([@bib19]), and scRNA-seq was plotted according to diffusion components (DCs) using software (<http://uofuhealth.utah.edu/huntsman/labs/>spike/d3.php) as described previously ([@bib19]). DC1 represents a continuum of relative enrichment from basal to luminal subtype. DC2 represents developmental time from primitive (E16 and E18) to P4 adult mammary cells occupy ends of the DC2 axis.(B) The abundance of *Dach1* transcripts was mapped upon the diffusion map scRNA-seq transcriptomics, in order to show the correlation with stage of development and relative abundance in the luminal versus basal subtypes. *Dach1* is expressed among multipotent fetal mammary stem cells in the embryo and among mixed lineage precursors prior to puberty *Dach1* expression was detected in adult basal cells (dark blue dots in lower-right corner) and (ERα^+^) luminal progenitors (light blue dots in upper-right corner).(C--F) *Dach1* RNA transcripts are expressed during post-natal development. (C) scRNA-seq of MECs derived from nulliparous, mid gestation, lactation, and post-involution mammary glands identified 15 clusters of MECs ([@bib3]). (D) Relative expression of Dach1 within each cluster type is shown colorimetrically, with relative expression shown in the bar to the right. (E) Dendrogram of clusters based on the log-transformed mean expression values of the 15 clusters. The red blocks show the cluster subtype in which *Dach1* is expressed based on the relative abundance of transcripts shown in (F). *Dach1* gene expression was detectable primarily in presumptive basal and myoepithelial cells (clusters C12, C13, and C14), and to a lesser degree also in luminal ERα^+^ (cluster C3) and luminal progenitor clusters (C6/7).

We next assessed *Dach1* transcript abundance in a second distinct transcriptomic analysis. The second study determined the gene expression profile of MECs across four adult developmental stages; nulliparous, mid gestation, lactation, and post involution ([@bib3]). The analysis of 23,184 adult cells identified 15 clusters representing different transcriptional cell states ([Figure 2](#fig2){ref-type="fig"}C). *Dach1* gene expression was detectable primarily in presumptive basal and myoepithelial cells (clusters C12, C13, and C14), and to a lesser degree also in luminal ERα^+^ (cluster C3) and luminal progenitor clusters (C6/7) ([Figures 2](#fig2){ref-type="fig"}D--2F).

Collectively these studies are consistent between distinct datasets and illustrate that Dach1 is expressed in fMaSCs and in both the adult basal and ERα^+^ luminal cells.

DACH1 Promotes Mammary Gland Stem Cell and Basal/Myoepithelial Cell Expansion {#sec2.3}
-----------------------------------------------------------------------------

To determine the functional consequence of *Dach1* gene deletion, cellular proliferation was assessed using Ki-67 immunohistochemistry. Ki-67 staining was reduced \>75% upon excision of the *Dach1* gene ([Figures 3](#fig3){ref-type="fig"}A and 3B). Apoptosis, as assessed by TUNEL staining, was very low in control mice and was not affected by *Dach1* deletion. ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2C). Treatment of tissues from *Dach1* deletion mice (*Dach1*^*fl/fl*^; *ROSA26*^*mTmGfl/Cre-ERT2*^ + tamoxifen) with DNase1, as a form of positive control, induced TUNEL staining in all the epithelial cells ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Mammary squashes were prepared ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). A careful counting of branches revealed a significant decrease in branching in the *Dach1*^*−/−*^ mammary gland ([Figure 3](#fig3){ref-type="fig"}C).Figure 3*Dach1* Gene Deletion Reduces Mammary Gland Cellular Proliferation, Ductal Branching, and Myoepithelial/Stem Cells(A) Cellular proliferation assessed by Ki-67 immunostaining with nuclei marked by DAPI staining (A).(B) As above, but quantified as mean ± SEM for n = 3 separate mice in each group. Data are shown for *Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmGfl*^ versus *Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmGfl*^ after tamoxifen treatment as shown in [Figure 1](#fig1){ref-type="fig"}A.(C) Ductal branching analysis (shown as mean ± SEM for n = 3 mice). Representative examples are shown at high magnification in [Figure S3](#mmc1){ref-type="supplementary-material"}.(D) A representative fluorescence-activated cell sorting (FACS) analysis from the mammary epithelium showing the separation of mT from mG cells, the subsequent separation of Lin^−^ cells and the apportioning of CD24/CD29 status.(E) The proportion of Lin^−^ cells (cells from mammary gland excluding vascular and hematopoietic cells) was determined by FACS analysis and quantified for n = 4 separate mice. The proportion of Lin^−^ cells was not significantly altered between genotypes.(F) The percentage of Lin^−^CD24^med^CD29^hi^ cells was determined upon FACS analysis for n = 4 separate mice in each group.(G) Luminal epithelial cells are shown as Lin^−^CD24^hi^ CD29^lo^ with data as mean ± SEM for n = 4 separate mice.

To determine the role of endogenous DACH1 on the proportion of breast cellular subtypes, fluorescence-activated cell sorting (FACS) analysis was conducted on the mammary gland from transgenic mice ([Figure 3](#fig3){ref-type="fig"}D). To enrich for basal cells, Lin^−^ cells were selected ([Figures 3](#fig3){ref-type="fig"}D and 3E), with subsequent gating for CD29^high^ and CD24^medium^ (basal) cells from tamoxifen-treated control (*Dach1*^*wt/wt*^*-Rosa26*^*mTmGfl/Cre-ERT2*^) and *Dach1*^*fl/fl*^ transgenic (*Dach1*^*fl/fl*^*-Rosa26*^*mTmGfl/Cre-ERT2*^) mice ([Figure 3](#fig3){ref-type="fig"}F). Several studies have shown the multilineage potential of cells in this subpopulation ([@bib40], [@bib47]). This population, herein referred to as basal cells, has previously been shown to be enriched with bipotential mammary stem cells (MaSCs) and gives rise to unipotent stem cells or long-lived progenitors for the basal/myoepithelial and luminal lineages ([@bib46]). The relative proportion of Lin^−^ CD24^med^ CD29^high^ was reduced \>40% in *Dach1*^*−/−*^ mammary gland ([Figure 3](#fig3){ref-type="fig"}D). Quantitation of the additional cell subtypes, based on epitope markers and FACS analysis revealed an increase in the luminal epithelial pool (CD24^high^ CD29^low^) in the *Dach1*^*−/−*^ mammary gland ([Figure 3](#fig3){ref-type="fig"}G).

To examine further the impact of endogenous DACH1 on the development of the basal versus the luminal epithelial cells, we conducted immunofluorescence analysis of the mammary glands using traditional cytokeratin lineage markers. Cytokeratin 5 (CK5) was used to identify basal epithelial cells, and CK8 was used for the identification of luminal epithelial cells. In the *Dach1*^*−/−*^ mammary gland epithelial cells, the relative abundance of CK5 was reduced and the relative abundance of CK8 was increased ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}).Figure 4*Dach1* Gene Deletion Reduces the Abundance of Mammary Gland Stem Cell and Ductal Cell Lineage Gene Targets(A) Immunofluorescent double staining for cytokeratin 5 (CK5) and CK8 showed that Dach1 gene deletion decreases the relative amount of CK5-positive cells versus CK8-positive cells.(B) Immunohistochemical staining for differentiation factors (*Gata3*, *Pml*, and *Pygo2*) in the mammary gland of *Dach1*^*+/+*^ versus *Dach1*^*−/−*^ (Cre deletion mice) (*Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmGfl*^ versus *Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmGfl*^). The red arrowheads indicate basal epithelial cells.(C) Quantitation of immunohistochemical staining shown as mean ± SEM for n = 3 separate mice.

DACH1 Enhances Abundance of Genes Governing Ductal Branching {#sec2.4}
------------------------------------------------------------

Because DACH1 loss reduced mammary duct branching, we next determined the effect of endogenous DACH1 on the expression of genes known to govern the process. Branching is associated with increased PYGO2 ([@bib20]), ELF5 ([@bib7]), PML, NOTCH1 ([@bib6]), and GATA3 ([@bib2]). Immunohistochemical analysis of the wild-type mammary gland identified PYGO2 in the luminal cells with occasional basal cells staining, PML in both luminal and epithelial cells, and GATA3 expression in the luminal cells (indicated with the arrows in [Figure 4](#fig4){ref-type="fig"}B). In the *Dach1*^*−/−*^ mammary gland the abundance of PYGO2, PML, and GATA3 were reduced ([Figures 4](#fig4){ref-type="fig"}B and 4C).

qPCR verified the reduction of *Dach1* mRNA ([Figure 5](#fig5){ref-type="fig"}A) and a reduction in the abundance of the mRNA for *Gata3*, *Elf5*, *Pml*, *Notch1*, and *Pygo2* ([Figures 5](#fig5){ref-type="fig"}B--5F) in the *Dach1*^*−/−*^ mammary gland. *Notch1* mRNA levels were modestly reduced ([Figure 5](#fig5){ref-type="fig"}E). Analysis of DACH1 binding to these target genes was assessed using chromatin immunoprecipitation sequencing conducted on a DACH1 stably transfected MDA-MB-231 breast cancer cell line ([@bib51], [@bib50]). Significant enrichment of DACH1 binding was identified at the target promoters for *Gata3*, *Elf5*, *Pml*, *Notch1*, and *Pygo2* ([Figures 5](#fig5){ref-type="fig"}G--5L). DACH1 enrichment was located at the transcriptional start site of each gene, consistent with the known binding of DACH1 to the transcription elongation regulator (TCERG) (TCERG1, also known as CA150 or TAF2S) ([@bib56]) and at CTCF sites ([Figures 5](#fig5){ref-type="fig"}H--5L).Figure 5DACH1 Occupies the Promoter Regions of Mammary Gland Stem Cell and Ductal Cell Lineage Gene Targets(A--F) qRT-PCR analysis of mRNA for genes participating in mammary gland stem cell and ductal development, (A) *Dach1*, (B) *Gata3*, (C) *Elf5*, (D)*Pml*, (E) *Notch1*, and (F) *Pygo2*, in the mammary gland of Cre deletion mice (*Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmGfl*^ versus *Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmGfl*^) with quantitation shown as mean ± SEM for n = 3 separate mice. *Notch1* mRNA levels were modestly reduced in the *Dach1*^*−/−*^ mammary gland.(G--L) Analysis of DACH1 binding to these target genes was assessed using chromatin immunoprecipitation sequencing assays conducted on DACH1 stable MDA-MB-231 cells (G). (H) *Gata3*, (I) *Elf5*, (J) *Pml*, (K) *Notch1*, and (L) *Pygo2*.

DACH1 Enhances Ductal Branching in Epithelial Cultures {#sec2.5}
------------------------------------------------------

LA-7 cells exhibit the normal mammary gland stem cell properties of self-renewal and multilineage differentiation *in vitro* and *in vivo* ([@bib58]). LA-7 cells keep the potentials to defferentiate to all the epithelial cell types present *in vivo* and, when cultured in 3D collagen matrix, develop organoids with 3D tubule-alveolar-like structures that morphologically and functionally recapitulate the 3D architecture of the mammary tree ([@bib58]). LA-7 cells expressing DACH1 or control cells seeded onto 3D collagen-generated ductal/acinar structures as assessed by phase contrast microscopy ([Figure 6](#fig6){ref-type="fig"}A). Branching occurred by day 7 and increased through day 14 and subsequently ([Figure 6](#fig6){ref-type="fig"}A). DACH1-transduced LA-7 cell sprouting was increased 2.3-fold ([Figure 6](#fig6){ref-type="fig"}B, n = 3 experiments, p \< 0.01, day 20). After day 14 in LA-7-DACH1 cells, the tubule structures were converted into lobular structures when compared with controls ([Figure 6](#fig6){ref-type="fig"}A). DACH1 increased β-casein abundance and reduced CD44 at day 4 when normalized to the β-actin loading control ([Figure 6](#fig6){ref-type="fig"}C). Transfection of LA-7 cells with the DACH1 expression vector increased DACH1 expression 3-fold, as determined by qPCR ([Figure 6](#fig6){ref-type="fig"}D). RT-PCR analysis showed a 2- to 3-fold increase in the luminal markers E-cadherin (CDH1) and CK18, when normalized to hypoxanthine phosphoribosyl (HPR); abundance of the surface glycoprotein CD44 was reduced 40% ([Figure 6](#fig6){ref-type="fig"}D, p \< 0.05). The ductal morphogenesis target Gata3 was induced 3-fold and Notch1 was induced 4.8-fold ([Figure 6](#fig6){ref-type="fig"}D).Figure 6DACH1 Induces Ductal Branching and Mammospheres in LA-7 Cells(A) Representative phase contrast microscopy images of LA-7 cells cultured on collagen plates (upper panels), LA-7 cells transduced with control vector (middle panel), or vector-expressing DACH1 (lower panels) are shown.(B and C) Cells were analyzed for ductal formation at day 20 (B). LA-7 tubule sprout number per view shown as mean ± SEM (C). Western blot with antibodies as indicated of either LA-7 cells transduced with control vector or DACH1 expression vector. β-Actin is used as a protein loading control.(D) RT-PCR analysis of mammary stem cell regulatory genes was conducted. Results are shown as mean ± SEM for n = 3 separate experiments. ^∗^p \< 0.05.(E) Immunofluorescence of LA-7 cells transfected with DACH1 or with empty vector, grown in 3D organoids structures. DACH1 reduced myoepithelial markers (CK14, green), whereas luminal markers (CDH1) were upregulated.(F) LA-7 cells, or LA-7 cells transduced with control vector or vector expressing DACH1, were analyzed for mammosphere formation. Cells were plated in limiting dilutions of 500 cells/1.4 mL of media and mammosphere (150--200 cells) were counted at day 8. Phase contrast image of a representative field is shown and the number of mammospheres (mean ± SEM is shown for n = 3 separate experiments, ^∗^p \< 0.01).(G) A separate clone of LA-7 cells transduced with DACH1 or vector control were grown as mammospheres in 24-well plates and representative images are shown at 2×.

We next examined the impact of DACH1 on the abundance of luminal versus myoepithelial cell lineage markers during LA-7 cell organoid formation using immunofluorescence. LA-7 cells transfected with DACH1 or with empty vector as a control, were cultured in collagen for 10 days and then digested with collagenase. The 3D structures were then embedded in OCT and sectioned with a cryotome. Organoids generated by LA-7 in which DACH1 was transfected express epithelial luminal markers (CDH1) but less of the myoepithelial markers (CK14) ([Figures 6](#fig6){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}).

Because endogenous DACH1 enhanced the proportion of Lin^−^ CD24^med^ CD29^high^, which we herein referred to as basal cells, we considered the possibility that DACH1 may drive the expansion of MaSCs and therefore deployed a surrogate assay of mammosphere formation using LA-7 cells. DACH1 transduction of LA-7 cells increased mammosphere number by 30% ([Figures 6](#fig6){ref-type="fig"}F and 6G, n = 3 separate experiments, p \< 0.01). Transduction efficiency of the LA-7 cells was 70%--80%. Thus, DACH1 promotes formation of mammary gland ducts and mammospheres in LA-7 cells.

DACH1 Restrains TGF-β Action in the Pubertal Mammary Gland *In Vivo* {#sec2.6}
--------------------------------------------------------------------

The TGF-β signaling pathway restrains mammary progenitor self-renewal ([@bib28]) and lineage commitment decisions, decreasing myoepithelial cell progenitors ([@bib27], [@bib28]). Furthermore, TGF-β is known to restrain mammary ductal branching ([@bib5], [@bib13], [@bib31], [@bib34], [@bib37]) ([Figure 7](#fig7){ref-type="fig"}A). We therefore determined the possible role of endogenous *Dach1* in restraining mammary gland TGF-β activity by first assessing the phosphorylation of SMADs. Immunohistochemical staining demonstrated increased phosphorylation of SMAD 2/3 and SMAD 1/5/8 in both the basal and luminal MECs ([Figures 7](#fig7){ref-type="fig"}B--7E).Figure 7*Dach1* Gene Deletion Activates TGF-β Signaling in the Mammary Gland(A) A summary of the mammary gland phenotype identified herein upon *Dach1* gene deletion, with comparison to the effect of *TGF-β* gene deletion summarized from the literature ([@bib13], [@bib31], [@bib5], [@bib34], [@bib37]).(B and C) Representative example (B) and quantitative analysis (C) of immunohistochemical staining for pSMAD2/3 in the mammary gland from mice shown as *Dach1*^*+/+*^ (*Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmGfl*^) and *DACH1^--/--^* (*Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmGfl*^).(D and E) Representative example of immunostaining for pSMAD 1/5/8 (D), with quantification (E) shown as mean ± SEM for n = 3 separate animals.(F and G) Western blots of Met-1 breast cancer cells transduced with a DACH1 expression vector using antibodies to the proteins as indicated (F) for p-SMAD2/3 and (G) for DACH1, p-SMAD1/5/8, and Cyclin D1.(H) Western blot of *Dach1*^*wt*^ versus *Dach1*^*−/−*^ 3T3 cells for SARA association after immune precipitation for Smad 2/3. S.E., short exposure; L.E., longer exposure. β-Actin is used as a protein loading control.

DACH1 Inhibits SMAD Association with Smad Anchor for Receptor Activation {#sec2.7}
------------------------------------------------------------------------

Reintroduction of DACH1 via a retroviral expression vector into the metastatic Met-1 breast cancer cell line, increased DACH1 abundance and reduced Smad anchor for receptor activation (SMAD) 2/3 phosphorylation ([Figure 7](#fig7){ref-type="fig"}F) and SMAD 1/5/8 phosphorylation ([Figure 7](#fig7){ref-type="fig"}G) in both the nuclear and cytoplasmic fractions. The scaffold protein SARA, also known as the zinc finger FYVE domain-containing protein 9 (ZFYVE9), brings SMAD 2/3 to TGF-β receptors, facilitating SMAD 2/3 activation and thereby augmenting TGF-β signaling ([@bib45]). The relative abundance of SARA was increased 4-fold upon *Dach1* deletion ([Figure 7](#fig7){ref-type="fig"}H). Immunoprecipitation (IP) with an antibody directed to SMAD 2/3 co-precipitated SARA; however, the relative abundance of SARA in the SMAD 2 IP was dramatically increased in the *Dach1*^*−/−*^ cells, consistent with a role for DACH1 to inhibit the SARA-SMAD 2/3 association and thereby reduce basal SMAD activity ([Figures 7](#fig7){ref-type="fig"}H, [S6](#mmc1){ref-type="supplementary-material"}B, and S6C).

Discussion {#sec3}
==========

DACH1 Skews Mammary Gland Lineage Development {#sec3.1}
---------------------------------------------

In this current study, we show that endogenous DACH1 increases the proportion of basal cells and reduces the proportion of luminal cells in the post-natal mammary gland. Interrogation of *Dach1* transcripts from scRNA-seq ([@bib19], [@bib26]) demonstrated that *Dach1* gene expression was detectable in multiple lineages and stages, including multipotent fMaSCs in the embryo and among MMPr prior to puberty. DACH1 expression was detected in presumptive basal and myoepithelial cells, adult basal cells and (ERα^+^), luminal progenitor, and in ERα^+^ luminal cells. The mechanism by which DACH1 alters the relative proportion of basal versus luminal cells may involve lineage skewing during differentiation, intrinsic effects in different lineage progenitors, or transitive effects from myoepithelial cells that normally restrain the luminal cell number in a juxtacrine/paracrine fashion and may involve both cell intrinsic or heterotypic signaling.

What might be the consequence of DACH1 increasing the proportion of basal cells? Myoepithelial cells express a variety of recognized tumor-suppressor proteins (p63, p73, 14-3-3-s, and maspin) and provide the interface between tumor cells of ductal carcinoma *in situ* and the microenvironment ([@bib36]), conveying antiangiogenic, antiproliferative, and anti-invasive properties. Previous studies have shown that DACH1 reduced growth of breast tumor cells in tissue culture and in immune-deficient mice ([@bib39], [@bib38], [@bib53], [@bib50]). Collectively, these studies suggest that DACH1 is required for normal myoepithelial cell number and function and may thereby play a regulatory role as "natural tumor suppressors" in the mammary gland (reviewed in [@bib1], [@bib4], [@bib25], [@bib35], [@bib43], [@bib44]).

DACH1 Promotes Mammary Gland Ductal Branching {#sec3.2}
---------------------------------------------

The current studies demonstrate that *Dach1* deletion reduced mammary gland ductal branching and DACH1 expression in LA-7 cells enhanced ductal branching. Prior studies demonstrated a role for DACH1 in promoting migration in several different cell types including fibroblasts ([@bib51]), MECs ([@bib51]), prostate epithelial cells ([@bib10]), and vascular endothelial cells ([@bib8]). TGF-β1 is a major negative regulator of mammary ductal branching, restricting end bud bifurcation and branch formation ([@bib18], [@bib21], [@bib42]). Epithelial cell or stromal expression of a dominant-negative TGF-β allele (dnIIR) increased mammary ductal branching ([@bib5]). *Dach1* deletion phenocopies TGF-β overactivity. The finding that *Dach1* gene deletion phenocopies TGF-β over activity, and that *Dach1* deletion results in TGF-β hyperactivity demonstrated by increased SMAD phosphorylation in the mammary gland, suggests that Dach1-mediated TGF-β restraint may govern the mammary gland ductal branching phenotype. SMAD phosphorylation was increased in both the basal and luminal cells. DACH1 was expressed in both basal and luminal cells during development; however, in the adult mammary gland, immunohistochemistry showed that DACH1 was predominantly in the basal cells, raising the possibility that Dach1 exerts both cell-autonomous and non-autonomous effects on TGF-β signaling.

Several other genes are essential for normal mammary duct development including *Esr1*, *Srib*, and *Ovol2*, and pubertal branching development is disrupted in mice lacking *GH*, *insulin-like growth factor 1* (*Igf1*), or *estrogen receptor α* (*Esr1*). DACH1 can inhibit IGF1 and ERα signaling to restrain EMT ([@bib16], [@bib39], [@bib50]), which may contribute to the mammary gland developmental changes of *Dach1*^*−/−*^ mice.

DACH1 Expands the Mammary Gland Stem Cell Population {#sec3.3}
----------------------------------------------------

Herein DACH1 enhanced LA-7 cell mammosphere formation and endogenous Dach1 enhanced the proportion of basal cells, characterized by CD24^med^CD29^hi^Lin^−^ cells, *in vivo*. The expansion of the basal cell population may be secondary to the restraint of TGF-β activity, as TGF-β decreases MEC repopulating activity ([@bib28]). Alternatively the expansion may be secondary to transcriptional effects by Dach1 on several target genes known to participate in the expansion of MaSCs, including PYGO2, NOTCH1, and BRCA1 ([@bib20], [@bib28], [@bib47]) ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). PML serves to enhance the transition of luminal progenitors to alveolar progenitors, which may in turn increase the myoepithelial progenitor pool. The histone methylation reader PYGO2, a coactivator of the WNT pathway, is necessary for suppressing luminal and alveolar differentiation of the MaSC-enriched population by coordinating the activity of the Wnt and Notch pathways ([@bib20]). GATA3 is a crucial regulator of the luminal lineage as GATA3 restrains luminal progenitors ([@bib2]). Herein DACH1 enhanced basal cells and restrained TGF-β activity, and TGF-β is known to restrain basal cell expansion. The frequency of basal cells and the development of breast cancer subtypes suggests that inactivation of lineage determinant proteins are mechanistically linked ([@bib47]). The current studies contrast with findings that Dach1 restrains breast cancer ([@bib50]) and brain cancer ([@bib48]) stem cells. These findings may reflect the dual effects of TGF-β early in the mammary gland as a tumor suppressor and at a later stage to evade immune surveillance and promote metastasis ([@bib29], [@bib30]).

Experimental Procedures {#sec4}
=======================

Transgenic Mice {#sec4.1}
---------------

All the animal studies were approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University. The *Dach1*^*fl/fl*^ mice ([@bib10], [@bib37]) (which remove the same section of the *Dach1* locus that is deleted in the knockout mice strain \[[@bib14]\]), were intercrossed with the *ROSA26*^CreERT2^ mice (expressing CRE-ERT2 fusion protein under the control of the ubiquitous *ROSA2*6 promoter; the mice were kindly provided by Dr. Thomas Ludwig at Columbia University, New York, NY). *Dach1*^*fl/fl*^ mice were mated with either *ROSA26*^*CreERT2/CreERT2*^ or *ROSA26*^mTmG/mTmG^ mice to generate *Dach1*^*fl/wt*^*ROSA26*^*CreERT2/CreERT2*^ (Cre mice) and *Dach1*^*fl/wt*^*ROSA26*^*mTmG/mTmG*^ (Cre reporter mice). *Dach1*^*fl/wt*^*ROSA26*^*CreERT2/+*^ mice were then mated with *Dach1*^*fl/wt*^*ROSA26*^*mTmG/+*^ mice to generate *Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmG*^ mice and *Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmG*^ littermates.

Immunohistochemistry, Immunofluorescence, and TUNEL Staining {#sec4.2}
------------------------------------------------------------

Immunohistochemical analysis of paraffin-embedded murine mammary gland tissues was conducted using a polyclonal DACH1 antibody (Proteintech, cat. no. 10,914-1-AP) ([@bib53]), anti-PYGO2 (Thermo Fisher Scientific, cat no. PA5-34878), anti-PML1 (Abcam, cat. no ab67761), anti-GATA3 (Santa Cruz Biotechnology, cat. no, sc-9009), anti-vWF (A0082, Dako), anti-phosphorylated SMAD2/3 (Santa Cruz Biotechnology, cat. no. sc-11769-R), or anti-phosphorylated SMAD1/5/8 (Ser 423/425) (Santa Cruz Biotechnology, cat. no. sc-12353-R). Immunofluorescent analysis of frozen mouse mammary gland was conducted using anti-Ki-67 clone SP6 rabbit monoclonal antibody (Abcam, cat. no. ab16667), anti-CK5 antibody (PRB-160P, Covance), rabbit polyclonal and/or anti-CK8 mouse monoclonal antibody (MMS-162P, Covance). DAPI was used as counter staining. Alexa Fluor 633- or Alexa Fluor 565-conjugated goat anti-rabbit antibody and Alexa Fluor 488-conjugated goat anti-mouse antibody were used as secondary antibodies ([@bib22], [@bib24]). Frozen sections of murine mammary gland tissues were used in immunofluorescence TUNEL staining. E-cadherin-FITC conjugated raised in mouse (BD Bioscience, cat no. 612131), cytokeratin 14 raised in rabbit (Sigma cat no. HAPA023040), and the secondary antibody raised in goat against rabbit IGG Alexa Fluor 488 (Life Technologies, cat no. A11034) were used in LA-7 cell immunofluorescence.

Cell Culture, Reagents, Mammosphere Assays, Expression Vectors, DNA Transfection, and Statistical Analyses {#sec4.3}
----------------------------------------------------------------------------------------------------------

The generation and culture of 3T3 and mouse embryonic fibroblasts derived from *Dach1*^*−/−*^ mice, the Met-1 breast cancer cell line ([@bib51], [@bib50]), and LA-7 rat mammary gland stem cells ([@bib58]) were described previously ([@bib51], [@bib50]). TGF-β was obtained from Calbiochem. Met-1 cells were infected with either MSCV-IRES-GFP (murine stem cell virus) or MSCV-DACH1-IRES-GFP ([@bib53]). LA7 cells were transiently transfected with Amaxa system (Amaxa Nucleofector Kit, Lonza) according to the manufacturer's protocol. 1 × 10^6^ LA7 cells were tansfected with 2 μg of each plasmid (GFP-empty, pKW-empty, and pKW-DACH1). GFP-plasmid was used as endogenous control of transfection. Data were expressed as the means ± SEM. Statistical analyses were performed using the Student\'s t test, and p values were \<0.05.

Tubule and Organoid Formation in 3D Culture {#sec4.4}
-------------------------------------------

For tubule/organoid formation, cells were suspended on ice in rat tail-derived collagen prepared as described previously ([@bib58]). Organoid cultures were examined daily with light microscopy to assess tubule and organoid formation and photographed at days 7, 14, and 20. Evaluation of branching was assessed 3 days after seeding by examining 10 tubules for each condition in 3 independent experiments.

IP and Western Blot {#sec4.5}
-------------------

IP and western blot assays were performed in cells as indicated. For each IP, 1 mL lysate (1 mg protein) and 2 μg anti-SMAD2/3 (BD, cat. no. 610843) or anti-SARA (Proteintech, cat. no. 14821-1-AP) were incubated overnight at 4°C. Immunoprecipitates were washed 5 times in IP buffer, and 30 μL of 2× sample buffer was added to the bead pellet. Laminin B1 antibody (Abcam, cat. no. ab16048) was used as an internal control for nuclear protein abundance and vinculin (Sigma, cat. no. V9131) was used as a control for cytoplasmic fraction enrichment. Polyclonal anti-Beta casein (Santa Cruz, cat no. SC-30042), monoclonal anti CD44 (Santa Cruz cat no. SC-53068), and polyclonal anti-Beta actin (Santa Cruz, cat no. SC-1615) were used in LA-7 cell Western-blot.

FACS Analysis of Stem Cells {#sec4.6}
---------------------------

FACS analysis for mammary epithelial stem cells was conducted as outlined in prior publications ([@bib17], [@bib23], [@bib40]). In brief, mammary glands were removed from 12-week-old *Dach1*^*fl/fl*^*ROSA26*^*CreERT2/mTmG*^ and *Dach1*^*wt/wt*^*ROSA26*^*CreERT2/mTmG*^ mice. Both strains of mice were treated with a 5-day pulse of tamoxifen when mice reached 6 weeks of age and were analyzed after a subsequent 2.5 months. The data were analyzed with FlowJo single-cell analysis software (Tree Star, Ashland, OR).

Real-Time qPCR {#sec4.7}
--------------

PCR analysis for luminal markers (Cdh1 \[E-cadherin\]), CK18, alveolar marker (β-casein), and CD44 was conducted of LA-7 mRNA as described previously ([@bib58]). Primers for all the genes/gene transcripts including 18s rRNA and HPRT (hypoxanthine-guanine phosphoribosyltransferase) transferase are listed in [Table S1](#mmc1){ref-type="supplementary-material"}, except Cdh1, CK18, and CD44 which described previously ([@bib58]).
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